Form 4: Cogent Biosciences Chief Medical Officer Granted Stock Options

Cogent Biosciences' Chief Medical Officer, Jessica Sachs, was granted 270,000 stock options on January 23, 2025, which vest over four years.

Summary

• Jessica Sachs, the Chief Medical Officer of Cogent Biosciences, was granted 270,000 stock options on January 23, 2025.
• The options have an exercise price of $8.89.
• These options will vest in equal monthly installments over a four-year period.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the Chief Medical Officer aligns her interests with the long-term success of the company.
• The vesting schedule encourages continued service and contribution from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of four years is typical for such grants, ensuring long-term commitment.
• The exercise price is set at a specific value, which is common practice.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the Chief Medical Officer to contribute to the company's success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cogent Biosciences, COGT, Jessica Sachs, Chief Medical Officer